An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28 is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Amyotrophic Lateral Sclerosis. SEO and diligence focus: BLZ945, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.